In the following video, health care editor/analyst David Williamson discusses the FDA advisory committee vote that sent shares of Arena Pharmaceuticals soaring over 70% in a single day. Obesity drug lorcaserin received an 18-4 recommendation supporting approval. What does this vote mean for Arena's competitors, and is the company poised for monster returns? For a closer look, watch the video and Fool On.
Arena is on the cutting edge for obesity treatment, yet it isn't one of the many dynamic recommendations made to Motley Fool Rule Breakers subscribers over the years. Now's a great time to discover the next rule-breaking multibagger that the newsletter has unearthed. It's a free report. Want it? Get it.
At the time thisarticle was published David Williamson holds no position in any company mentioned.Click hereto see his holdings and a short bio. The Motley Fool has adisclosure policy. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. Try any of our Foolish newsletter servicesfree for 30 days.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.